Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss

 
• By Alaric DeArment

Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.

Pfizer may be able to soften the blow of an impendent exclusivity loss for Xtandi • Source: Shutterstock

More from Clinical Trials

More from R&D